As the 2019–20 flu season gets underway, Johns Hopkins Medicine experts will be available throughout the season to talk with your newsroom about the epidemiology of this year’s virus, as well as provide important information about this year’s vaccine. Flu cases have already begun to appear in the U.S. Flu activity tends to increase in October and can run as late as May.
Infectious disease experts David Cennimo at Rutgers New Jersey Medical School and Tanaya Bhowmick at Rutgers Robert Wood Johnson Medical School discuss this year’s flu season, the effectiveness of the vaccine and how you can protect yourself.
NIH contract award of up to $132 million will further ongoing efforts to develop a long-lasting vaccine
The University of Georgia has signed a contract with the National Institutes of Health for an initial award of $8 million to develop a new, more advanced influenza vaccine designed to protect against multiple strains of influenza virus in a single dose. The total funding could be up to $130 million over seven years if all contract options are exercised.
As part of a massive national effort to improve and modernize flu shots, the Duke Human Vaccine Institute has received three research contracts from the National Institute of Allergy and Infectious Diseases (NIAID), with an initial award of approximately $29.6 million in first-year funding.
In mid-August 2019, human clinical trials were halted in the current Ebola epidemic that has claimed more than 2,100 lives in Africa. The findings resulted in the discontinuation of two of the drugs in the trial. Future patients will be randomly assigned to receive either REGN-EB3 (Regeneron) or mAb114 (Ridgeback Biotherapeutics) in an extension phase of the study. Texas Biomedical Research Institute scientists in the Institute’s Biosafety Level 4 contract research program conducted preclinical testing of several of the compounds in the trial, working with Regeneron and the Biomedical Advanced Research and Development Authority (BARDA).
Wistar was awarded two major grants totaling more than $12 million from the National Institute on Drug Abuse (NIDA), part of the National Institutes of Health, to fund an international multidisciplinary clinical research consortium spearheaded by Wistar’s HIV Research Program.
Value in Health, the official journal of ISPOR—the professional society for health economics and outcomes research, announced today the publication of research demonstrating that discrete choice experiments are able to predict real-world healthcare choices.
The National Institute of Allergy and Infectious Diseases research contract is one of the largest ever awarded to UMSOM and includes an initial award of approximately $2.5 million to conduct clinical testing of influenza vaccines. Total funding over seven years could be as much as $201 million if all options are exercised in the NIAID contract.
A novel vaccine at Penn Medicine protected almost all animal subjects exposed to the herpes virus
The UM School of Medicine's Contract awarded by the National Institute of Allergy and Infectious Diseases could fund up to $201 Million in influenza research over seven years.
Spending bills released by Senate Appropriations Committee Wednesday demonstrate encouraging recognition of some of the most urgent health challenges threatening individual and public health at home and abroad. At the same time, the bills fall short of the comprehensive commitments necessary to fully effective responses.
By scraping tubeworms off the bottom of boats in the San Diego harbor to study them, San Diego State University
Patrick Wilson, PhD, professor of medicine and rheumatology at the University of Chicago, and a group of researchers from three other institutions have received aGrand Challenge for Universal Influenza Vaccine Development grant – a $12 million initiative funded by the Bill & Melinda Gates Foundation and Flu Lab.
In a study published in the journal Cancer Immunology Research, University of North Carolina Lineberger Comprehensive Cancer Center researchers reported on the discovery of a method for predicting whether abnormal proteins produced by cancer cells could trigger an immune response.
In the game against an essentially unlimited pool of virus threats, humanity is seriously outmatched. In order to shift the balance, scientists need to change the game.
Parents who take paid family leave after the birth of a newborn are more likely to have their child vaccinated on time compared to those who do not, according to new research from Binghamton University, State University of New York.
CARB-X, an international funder of efforts to fight antimicrobial resistance, is awarding up to $15 million to develop a strep throat vaccine based on original research at UC San Diego.
Researchers at Washington University School of Medicine in St. Louis and the biotech startup VaxNewMo have developed a vaccine that is effective, in mice, against hypervirulent strains of Klebsiella that can cause life-threatening infections in healthy adults.
Melanoma is a deadly form of skin cancer that has been increasing in the U.S. for the past 30 years. Nearly 100,000 new cases of melanoma are diagnosed every year, and 20 Americans die every day from it
The growing number of children arriving at Texas schools unvaccinated makes the state increasingly vulnerable to measles outbreaks. A 5% further decrease in vaccination rates that have been on a downward trend since 2003 would increase the size of a potential measles outbreak by up to 4,000%.
Three in 10 parents polled say that their child’s primary care office should ask parents who refuse all vaccines to find another health provider.
New research from Cornell University details how two highly lethal viruses have greater pathogenic potential when their proteins are combined.
For researchers with The Ohio State University College of Veterinary Medicine, the work to identify new flu strains and increase the effectiveness of the flu vaccine begins in an unlikely place – pig barns at state and county fairs nationwide.
A new study, led by researchers at La Jolla Institute for Immunology (LJI), identified and then reverse engineered the molecular properties shared by antibodies that are particularly efficient at inactivating or “neutralizing” Lassa virus providing a map for rational vaccine design.
Below are summaries of recent Fred Hutch research findings, with links for additional background and media contacts.
Inoviruses are filamentous viruses with small, single-stranded DNA genomes. Applying machine learning to more than 70,000 microbial and metagenome datasets, a team led by JGI scientists identified more than 10,000 inovirus-like sequences compared to the 56 previously known inovirus genomes.
Women tend to have a greater immune response to a flu vaccination compared to men, but their advantage largely disappears as they age and their estrogen levels decline, suggests a study from researchers at the Johns Hopkins Bloomberg School of Public Health.
A new study, led by researchers from the University of California, Irvine (UCI), uncovers the long-sought-after, three-dimensional structure of a toxin primarily responsible for devastating Clostridium difficile infection (CDI).
New estimates find dangerous stagnation of global vaccination rates, due to conflict, inequality and complacency
A virus 100% fatal in humans who are not vaccinated.
Parents given a handout with flu facts at their pediatrician’s office were significantly more likely to get their kids vaccinated before the end of flu season, Columbia pediatricians have found.
Public perceptions about how scientific evidence supporting the HPV vaccine is portrayed in society and media may influence whether individuals support public health measures to increase HPV vaccination.
In a new study, published on June 25, 2019, in the journal eLife, the researchers report that higher levels of doublets can be found in people with severe cases of tuberculosis or dengue fever.
In honor of philanthropist Phyllis Mailman, The Mailman Foundation, the Joshua Mailman Foundation, and The Tow Foundation, have together endowed the Phyllis Mailman Professorship to support groundbreaking emerging infectious disease research at the Joseph L. Mailman School of Public Health at Columbia University. The endowed professorship will be based in the Mailman School’s world-class Center for Infection and Immunity (CII), led by director Dr. W. Ian Lipkin, a globally-recognized microbe hunter who has identified more than 1,500 novel viruses. The newly created faculty position will support a distinguished researcher in the field of emerging infectious diseases.
The Senate Health, Education, Labor and Pensions Committee hearing today on the Lower Health Care Costs Act provides a valuable opportunity for lawmakers to address challenges compromising access to and uptake of vaccines that are among our most important public health tools.
Duke researchers describe a previously unidentified route for antibodies to be transferred from the mother to the fetus, illuminating a potential way to capitalize on this process to control when and how certain antibodies are shared.
Vaccinating babies against a virus that causes childhood “stomach flu” greatly reduces their chance of getting so sick that they need hospital care, a new study shows. But the study also reveals a surprise: Getting fully vaccinated against rotavirus in the first months of life is associated with a lower risk of developing Type 1 diabetes later on.
Every day, there are more than 1 million new cases of curable sexually transmitted infections (STIs) among people aged 15-49 years, according to data released today by the World Health Organization.
A public health, police, and military partnership to reduce the mosquito population in Sri Lanka resulted in a more than 50-percent reduction in dengue, as well as cost savings, finds a study from an international team of researchers led by NYU College of Global Public Health. The findings are published in The Lancet Planetary Health.
Researchers at Washington University School of Medicine in St. Louis and the Africa Health Research Institute have identified a master cell that coordinates the body’s immune defenses in the crucial early days after infection. Boosting the activity of such cells could help reduce the millions of new infections that occur worldwide every year.
Below are summaries of recent Fred Hutch research, with links for additional background and media contacts.
As part of a program called the Congressionally Directed Medical Research Program, the DOD is awarding Texas Biomedical Research Institute $2 million over the next three years to study a promising experimental Zika vaccine.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right